产品
编 号：F456268
分子式：C6H13N5
分子量：155.2
分子式：C6H13N5
分子量：155.2
产品类型
规格
价格
是否有货
结构图
CAS No: 775351-65-0
产品详情
生物活性：
Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.
体内研究：
Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, restores normal glucose tolerance, and improves insulin sensitivity.Animal Model:Male C57BL/6JOlaHsd mice (4 weeks old)
Dosage:200 mg/kg
Administration:Oral gavage; b.i.d.; 6 weeks
Result:A slight decrease in body weight and food intake associated with some diarrhea was observed but only during the first few days of treatment.
体外研究：
Preincubation with Imeglimin (10?mM for 4?h or 100?μM for 24?h) fully prevents tert-butylhydroperoxide (tBH)-induced cell death.
Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.
体内研究：
Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, restores normal glucose tolerance, and improves insulin sensitivity.Animal Model:Male C57BL/6JOlaHsd mice (4 weeks old)
Dosage:200 mg/kg
Administration:Oral gavage; b.i.d.; 6 weeks
Result:A slight decrease in body weight and food intake associated with some diarrhea was observed but only during the first few days of treatment.
体外研究：
Preincubation with Imeglimin (10?mM for 4?h or 100?μM for 24?h) fully prevents tert-butylhydroperoxide (tBH)-induced cell death.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备